About
Profile
BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
BMRN
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M
- BioMarin appoints Alexander Hardy as president and chief executive officer
- BioMarin Pharmaceutical Q3 2023 Earnings Preview
- Bernstein upgrades BioMarin to market perform, citing valuation
- FDA approves use of BioMarin drug Voxzogo in children under 5
- BioMarin a market perform at Raymond James due to growth concerns
- BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line
- BioMarin Pharmaceutical Q2 2023 Earnings Preview
- BioMarin upgraded at BMO after FDA nod for hemophilia A therapy
- BioMarin granted FDA nod for hemophilia A gene therapy
- Eli Lilly, Humana among best health care names in defensive environment - BofA
- BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M
- BioMarin Pharmaceutical Q1 2023 Earnings Preview
- What is behind biotech M&A resurgence?
- FDA to back accelerated approval pathway for gene therapies
- BioMarin seeks FDA nod to expand use of its Voxzogo treatment in children under five
- BioMarin's Roctavian gets FDA action date extended to end of June
- BridgeBio soars 55% after Phase 2 data for achondroplasia candidate
- BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M
- BioMarin Pharmaceutical Q4 2022 Earnings Preview